AI-assisted regulatory intelligence and standard tracking

Problem class

FDA launched its internal AI system "Elsa" in June 2025, which analyzes adverse event reports, compliance data, 483 observations, and historical inspection outcomes to prioritize high-risk facilities for inspection. The regulator itself is using AI — the regulated must follow.

Over-reliance on AI without human expert review — AI generates fictitious guidances and references (hallucinations documented by PDA practitioners) — and shadow use of LLMs by analysts without governance — specifically addressed by FDA/EMA 2026 guidance — are the dominant risk patterns.

Mechanism

Uses LLMs and NLP to continuously monitor, interpret, and assess the impact of regulatory changes across jurisdictions. Capabilities include automated scanning of agency websites and guidance updates, instant summarization of lengthy regulatory documents, version comparison (draft versus final), gap analysis against current compliance status, impact assessment for specific products/markets, multilingual support preserving legal nuance, and natural-language Q&A.

Regulatory milestones for AI itself. In January 2025, FDA issued its first comprehensive AI guidance proposing a 7-step risk-based credibility assessment framework for AI supporting regulatory decisions. In January 2026, FDA and EMA jointly released "Guiding Principles of Good AI Practice in Drug Development," addressing "shadow use" of LLMs and mandating continuous monitoring for "data drift." In December 2025, 26 organizations signed the EU AI Act's voluntary Code of Practice (including Amazon, Anthropic, Google, IBM, Microsoft, OpenAI; Meta refused).

Required inputs

• Document Control (to integrate regulatory change impacts into procedures)
• Regulatory intelligence program with subject-matter experts
• Data governance framework (for AI-generated compliance output validation)

Produced outputs

• Regulatory change alerts with impact assessments rated High/Medium/Low
• Version comparison reports (draft vs. final regulatory texts)
• Gap analysis against current SOPs, procedures, and filings
• Compliance task assignments (auto-generated from regulatory changes)
• Multilingual regulatory summaries with jurisdiction coverage
• Natural-language Q&A interface for regulatory queries with cited answers

Industries where this is standard

• Pharmaceuticals (100% of top 20 pharma companies use Clarivate Cortellis per their data)
• Medical devices (FDA/EMA AI guidance directly applies)
• Financial services (Norm Ai, Compliance.ai — Archer)
• Chemical/industrial (EU REACH, CLP regulation tracking)
• Food safety (FDA FSMA, EU food law tracking)

Counterexamples

• Over-reliance on AI without human expert review — AI generates fictitious guidances and references (hallucinations documented by PDA practitioners).
• Alert fatigue from too many regulatory change notifications without prioritization.
• False confidence in AI interpretation — LLMs may underrepresent regulations from non-English jurisdictions, introducing geographic bias.
• Shadow use of LLMs by analysts without governance — specifically addressed by the FDA/EMA 2026 guidance.
• Lack of validation workflow for AI-generated compliance outputs.

Representative implementations

• Clarivate Cortellis Regulatory Intelligence — used by 100% of the top 20 pharma companies; 300,000+ regulatory reports across 80+ global markets; AI Regulatory Assistant (launched August 2025) enables natural-language Q&A with cited, context-aware answers and multilingual support. Moderna reported it would "save significant time and resources."
• Regology — industry-agnostic global regulatory intelligence with AI Agents and a "Reggi" generative AI assistant.
• Compliance.ai (now part of Archer) — purpose-built ML models mapping regulatory changes to internal policies and auto-generating task assignments.
• Norm Ai — financial services focus; board includes former SEC General Counsel.
• FDA "Elsa" (June 2025) — internal AI for prioritizing high-risk facilities for inspection.
• One proof-of-concept project ingesting 100 health authority guidelines achieved accurate LLM responses in ~77% of cases.

Common tooling categories

Regulatory intelligence platforms (Clarivate Cortellis, Regology, Compliance.ai/Archer), LLM-powered document comparison tools, RAG-based regulatory Q&A systems, automated task assignment and change management integrations.

Regulatory anchors

FDA AI Guidance (January 2025 — 7-step risk-based credibility assessment framework), FDA/EMA "Guiding Principles of Good AI Practice in Drug Development" (January 2026), EU AI Act voluntary Code of Practice (December 2025), ICH Q10 (change control integration), ISO 9001:2015 Clause 9.3 (management review inputs).